EGFR and lung adenocarcinoma: Osimertinib, a third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI), remains the standard first-line systemic therapy for metastatic EGFR-mutant lung adenocarcinoma [1].